Document is current
Any future updates will be listed below
-
Authors
Neu, Marie A.
Ortmüller, Franziska
Robinson, Abigale L.
Dreismickenbecker, Elias
Otto, Henrike
Wypyrsczyk, Lena
Kühn, Mareike
Wessa, Michèle
Tüscher, Oliver
Faber, Joerg
,
Baader, Tobias Christian
Balduzzi, Adriana
Bauer, Nikolai
Bækgaard Larsen, Hanne
Beller, Ronja
Bloch, Wilhelm
Fiuza-Luces, Carmen
Fridh, Martin Kaj
Götte, Miriam
Hansen, Martin Bjørn
Heißerer, Barbara
Javelle, Florian
Karguth, Nina
Kitanovski, Lidija
Konda, Barbara
Lanfranconi, Francesca
Lucia, Alejandro
Marriott, Hayley
Mongondry, Rodolf
Moriggi, Tommaso Pietro
Paul, Norbert W.
Peli, Linda
Pérol, Olivia
Rizvi, Katie
Ravnik, Domen
Santa Cruz Ramos, Eva
Rovan, Meta
Solera-Sanchez, Alba
Spreafico, Filippo
Stefanović, Milica
Watson, Eila
Wiskemann, Joachim
Wright, Peter
Zardo, William
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 31 October 2025
Accepted: 17 February 2026
First Online: 26 February 2026
Declarations
:
: The Mainz Resilience Assessment in Childhood Cancer (MRAcc) was developed within the EU Horizon 2020-funded FORTEe project. The overall FORTEe study was approved by the Ethics Committee of the Rhineland-Palatinate Chamber of Physicians (application number 2021–15904) on August 4, 2021, with additional approvals from local ethics committees where applicable. All procedures performed in this study are in accordance with the 1964 Declaration of Helsinki and its later amendments. Cognitive pretesting was conducted within the approved FORTEe framework, and written informed consent (and/or parental consent for minors) was obtained from all participants prior to participation.This manuscript only describes the design and development process of the MRAcc. No other data from human participants were collected or analyzed for this publication.
: Not applicable.
: The authors declare no competing interests.
